The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton ...
Azitra is also progressing ATR-01, a preclinical program targeting ichthyosis vulgaris, with the goal of submitting an IND submission in 2026. The ATR-12, ATR-04 and ATR-01 programs were developed ...
BRANFORD, Conn., Aug. 27, 2025 /PRNewswire/ -- Azitra, Inc. (AZTR) ("Azitra"), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today ...
CHICAGO, Nov. 8, 2021/PRNewswire/ -- Advanced Technology Recycling (ATR) announces a new program that will help customers transform e-Waste into valuable e-Commodities as prices and material shortages ...
This localized campaign demonstrates ATR’s commitment to making secure, sustainable, and cost-effective IT asset management more accessible to new clients in the region. The new program enables ...
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0), a biopharmaceutical company advancing cancer therapies ...
Azitra (AZTR) is developing ATR04-484 for the treatment of EGFR inhibitor-associated rash with plans to dose first patient in Phase 1/2 trial in the first half of 2025 BRANFORD, Conn., April 25, 2025 ...
PENSACOLA, Fla., June 23, 2025 (GLOBE NEWSWIRE) -- Advanced Technology Recycling (ATR), a national leader in IT asset disposition (ITAD) and R2v3/RIOS certified electronics recycling, is excited to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback